Daiichi Sankyo Company, Limited · TSE:4568

Daiichi Sankyo — Q2 FY2015 Earnings Presentation

51 slides from Daiichi Sankyo's earnings presentation, Nov 2, 2015

  1. Slide 1: Top Management Presentation: Results for Q2 FY2015

    Top Management Presentation Results for Q2 FY2015 (April 1 – September 30, 2015) DAIICHI SANKYO CO., LTD Joji Nakayama President and CEO November 2, 2015

  2. Slide 2: Today's Topics

    Today’s Topics  FY2015 Q2 YTD Results  FY2015 revised consolidated forecast  Major management topics  Edoxaban business update  Trasformation of Daiichi Sankyo Inc.  R&D update  Luitpold business update 1

  3. Slide 3: FY2015 Q2 YTD Results

    FY2015 Q2 YTD Results 2

  4. Slide 4: Overview of FY2015 Q2 YTD Results (JPY Bn)

    Overview of FY2015 Q2 YTD Results (JPY Bn) FY2014 Q2 YTD FY2015 Q2 YTD YoY Results *1 Results +11.4% Revenue 429.6 478.8 +49.2 Cost of Sales 130.8 148.9 +18.1 SG&A Expenses 153.7 144.5 -9.2 R&D Expenses 84.9 88.4 +3.5 +61.0% Operating Profit 60.2 97.0 +36.8 Profit before tax 62.2 90.8 +28.6 +92.8% P

  5. Slide 5: Revenue

    Revenue Positive Negative Factors Factors Increased by 49.2 JPY Bn Decline in Daiichi Sankyo Europe offsetted by growth of Japan, Luitpold and ASCA with Forex (JPY Bn) FY2014 Results 429.6 Japan Positive: Nexium +6.6 Lixana +5.2 Japan Memary +3.7 Pralia +2.4 (incl. Vaccines, OTC) 6.2 Teneria +2.0 Ef

  6. Slide 6: Operating Profit

    Operating Profit Positive Negative Factors Factors Increased by 36.8 JPY Bn due to increased revenue, decreased R&D and SG&A expenses and special items absorbing increased cost of sales and forex impact (JPY Bn) FY2014 Results 60.2 49.2 Revenue +49.2 Revenue 60.2 incl. forex impact 23.8 Cost of Sale

  7. Slide 7: Profit attributable to owners of the Company

    Profit attributable to Positive Negative Factors Factors owners of the Company Increased by 34.0 JPY Bn due to increased operating profit Expenses relating to the sales of the Sun Pharma shares is booked as financial expenses (JPY Bn) FY2014 Results 36.7 Operating Profit 36.8 Financial Income Financ

  8. Slide 8: Major business units

    Major business units (JPY Bn) FY2014 FY2015 vs. Revised YoY Q2 YTD Results Q2 YTD Results Forecast (%) Japan 222.6 227.8 +5.2 46.4% Daiichi Sankyo Healthcare 22.7 24.6 +2.0 50.3% Daiichi Sankyo Inc. 78.1 93.4 +15.2 53.0% Olmesartan 47.2 57.1 +9.9 56.6% Welchol 21.8 24.2 +2.4 51.5% Effient 8.5 10.6 +

  9. Slide 9: Major products in Japan

    Major products in Japan (JPY Bn) FY2014 FY2015 vs. Revised Q2 YTD Q2 YTD YoY Forecast (%) Results Results Olmetec anti-hypertension 37.8 36.2 -1.6 45.8% anti-ulcer Nexium (Proton Pump Inhibitor) 32.1 38.7 +6.6 50.2% Memary treatment for Alzheimer 16.8 20.5 +3.7 43.6% analgesic and anti- Loxonin infl

  10. Slide 10: FY2015 revised consolidated forecast

    FY2015 revised consolidated forecast 9

  11. Slide 11: FY2015 revised consolidated forecast

    FY2015 revised consolidated forecast (JPY Bn) FY 2015 FY 2015 vs. Forecast Revised Forecast Forecast (as of Jul.) (as of Oct.) (as of Jul.) Major factors ・Delay of entry of Welchol GEs ・Good performance of products Revenue 950.0 980.0 +30.0 of Luitpold and Nexium Cost of Sales 302.0 314.0 +12.0 Majo

  12. Slide 12: Major management topics: Edoxaban business update

    Major management topics ・Edoxaban business update ・Transformation of Daiichi Sankyo, Inc. ・R&D update 11

  13. Slide 13: Edoxaban business update: Japan (Lixiana)

    Edoxaban business update: Japan (Lixiana)  Sales growing steadily  Approved and launched for DVT-OS in 2011  Approved for AF and VTE in Sep 2014  Sales growing steadily for FY 2015 (5.4 JPY Bn for Q2 YTD due to in VTE especially)  Revised sales forecast in Jul 2015: 5.0  11.0 JPY Bn M JPY (%)

  14. Slide 14: Edoxaban business update: US (Savaysa)

    Edoxaban business update: US (Savaysa)  Approved(Jan), Launched(Feb)  AF: indicated only for patients with CrCL ≤95 mL/min  VTE: without limitation of use  Negotiations with payers are on-going  Listed on the formularies of a few Medicare part D plans in 2016 in the non-preferred brand position

  15. Slide 15: Edoxaban business update: EU (Lixiana)

    Edoxaban business update: EU (Lixiana)  Making good start in each country  Approved by EC with no limitation of use (Jun)  Launched in Switzerland (May), UK (Jul), Germany (Aug) and Ireland (Sep)  Recommendation for VTE (Aug) and AF (Sep) by NICE  NOAC market is growing steadily in EU countries

  16. Slide 16: Edoxaban business update: other regions

    Edoxaban business update: other regions  Approved in Korea (Aug)  Filed NDA in China, Hong Kong, Taiwan, Thailand, Australia, Canada and Brazil 15

  17. Slide 17: Edoxaban business update: LCM others

    Edoxaban business update: LCM others  LCM & others  ENSURE AF (Cardioversion) - - NVAF undergoing electrical cardioversion, initiated in Mar 2014  The Hokusai-VTE Cancer - - VTE associated with cancer, initiated in Jun 2015  ETNA - - To collect real-world’s safety and efficacy date in the EU, Ja

  18. Slide 18: Major management topics: Transformation of Daiichi Sankyo, Inc.

    Major management topics ・Edoxaban business update ・Transformation of Daiichi Sankyo, Inc. ・R&D update 17

  19. Slide 19: DSI: Shift in product portfolio

    DSI: Shift in product portfolio With the LOE of Benicar and Welchol etc., DSI will transition from a maturing primary care product portfolio to a differentiated specialty portfolio centering on Pain and Oncology  New products  Current products CL-108 Pain Mirogabalin Tivantinib Quizartinib Patritu

  20. Slide 20: Transform DSI (U.S.) to a specialist-driven company

    Transform DSI (U.S.) to a specialist-driven company  Transform DSI to a company with;  Differentiated specialty portfolio  Long-term opportunities in cardiovascular, pain, and oncology markets  Agile, efficient, customer-centric operating model  To prepare for these opportunities, DSI will stre

  21. Slide 21: Major management topics: R&D update

    Major management topics ・Edoxaban business update ・Transform of Daiichi Sankyo, Inc. ・R&D update 20

  22. Slide 22: Progress of Major R&D pipeline

    Progress of Major R&D pipeline Change after FY2015 Q1 financial announcement  Consistent progress of projects in late phase development  Pexidartinib (PLX3397) Treatment of tenosynovial giant cell tumor (TGCT)  Breakthrough Therapy Designation * by the FDA Tenosynovial Giant Cell Tumor (TGCT) A p

  23. Slide 23: Progress of Major R&D pipeline

    Progress of Major R&D pipeline Change after FY2015 Q1 financial announcement  Consistent progress of projects in late phase development  CL-108: opioid-containing formulation  Third Phase 3 clinical trial of CL-108 met its primary endpoints  Results from the study with patients who experienced m

  24. Slide 24: Progress of Major R&D pipeline

    Progress of Major R&D pipeline Change after FY2015 Q1 financial announcement  Enrichment of innovative pipeline  The first clinical entry of DS-originated ADC* and challenge for unmet medical needs: new phase 1 entry  DS-8201: Antineoplastic drug (Anti-HER2** ADC)  DS-2330: Hyperphosphatemia tre

  25. Slide 25: DS-originated ADC clinical entering

    DS-originated ADC clinical entering  DS-8201: treatment for malignant tumor  The first antibody-drug conjugate utilizing DS-originated ADC technology entered into clinical phase  Topoisomerase I inhibitor is connected to anti-HER2 antibody through a linker  Characteristics: DS-8201 carries large

  26. Slide 26: Portfolio enhancement in thrombosis franchise

    Portfolio enhancement in thrombosis franchise  DS-9231 / TS23 α2-PI* inactivating antibody  Licensor: Translational Sciences Inc. (Memphis, Tennessee, US)  Global right for exclusive development and commercialization  Currently in Phase 1  To meet unmet medical needs for safe thrombus dissoluti

  27. Slide 27: In-licensing flu vaccine of new value-added formulation

    In-licensing flu vaccine of new value-added formulation  VN-0107/MEDI3250 Nasal spray live attenuated influenza vaccine, quadrivalent (US brand name: FluMist® Quadrivalent)  Licenser: US MedImmune (global biologics research and development arm of AstraZeneca)  Current development stage: J-NDA pre

  28. Slide 28: Major R&D pipeline

    Major R&D pipeline As of October 2015 Therapeutic area Phase 1 Phase 2 Phase 3 Application  DS-1040  CS-3150 (JP)  Prasugrel (JP)  Edoxaban (ASCA etc.) (Acute ischemic stroke / TAFIa inhibitor) (Hypertension ・ DM nephropathy / (CS-747 / ischemic stroke / anti- (DU-176b / AF / oral factor Xa inhi

  29. Slide 29: DS R&D Day 2015

    DS R&D Day 2015  Date : December 14, 2015, Monday at 3 pm  Location : Daiichi Sankyo Co. Ltd Nihonbashi HQ  Contents : Oncology Strategy, Update on Phase 3 projects etc.  Speaker : Dr. Glenn Gormley (Sr. Executive Corporate Office, Global R&D head) 28

  30. Slide 30: Slide 30

  31. Slide 31: Luitpold Business Update

    Luitpold Business Update Mary Jane Helenek President & CEO, Luitpold Pharmaceuticals, Inc. 30

  32. Slide 32: Luitpold Pharmaceuticals, Inc. (LPI)

    Luitpold Pharmaceuticals, Inc. (LPI) • US-based specialty pharma • Headquarters located in Shirley, NY • Five locations in US • Total employees: 880 Shirley, NY HQ and Plant Norristown, PA Clin. Dev. and MA New Albany, OH R&D and Plant Hilliard, OH Plant Columbus, OH QC/QA (for Ohio) 31

  33. Slide 33: LPI - A Diversified Specialty Company

    LPI - A Diversified Specialty Company LPI successfully competes in high value specialty branded & generic injectable market segments. Business Domains Strategic Imperatives Build Injectafer into our IRON FRANCHISE flagship product & (> 50% share of non HD segment) market leader GENERIC INJECTABLE Ma

  34. Slide 34: LPI - A Diversified Specialty Company

    LPI - A Diversified Specialty Company LPI successfully competes in high value specialty branded & generic injectable market segments. Business Domains Strategic Imperatives Build Injectafer into our IRON FRANCHISE flagship product & (> 50% share of non HD segment) market leader GENERIC INJECTABLE Ma

  35. Slide 35: What Is Iron Deficiency Anemia (IDA)?

    What Is Iron Deficiency Anemia (IDA)? • Iron is an integral component for hemoglobin in red blood cell (RBC), which is essential for oxygen transportation from lungs to the rest of the body. • When demand for iron exceeds supply, iron depletion can occur, affecting RBC’s function and causing anemia

  36. Slide 36: Cause of IDA

    Cause of IDA* Inadequate Inadequate Blood Loss Dietary Intake GI Absorption • Restricted diet • Malabsorption syndromes / • Surgery • Chronic dysfunctional GI conditions • GI bleeding alcoholism  e.g. IBD, bariatric surgery • Bleeding by • Drug/food interactions Increased Iron cancer • Upper gastro

  37. Slide 37: IDA population & treatment options are growing

    IDA population & Treatment Options are Growing US IDA Population from Associated Etiologies Primary Disease % IDA 10 CHF** Alone 17% 9 8 IBD** 36-76% 7 Celiac Disease 46% Millions 6 Gastric Bypass 24% Injectafer Iron Dextran Oral Iron 5 Cancer 7- 42% 4 3 HUB**/General IDA in Women 100% 2 1 Post Part

  38. Slide 38: Real Challenges in Current Iron Therapies

    Real Challenges in Current Iron Therapies Intolerance / • Difficult-to-tolerate side effects unsatisfactory • Pill burden / Length of treatment response to • Impaired absorption in a variety of oral iron circumstances Safety concerns • Hypersensitivity and other reactions with IV irons • Black box w

  39. Slide 39: Venofer: The IV iron Market Share Leader

    Venofer®: The IV iron Market Share Leader • “Lower-dose” IV iron • Treatment of IDA in patients with CKD  Adult and pediatric • Safety drives treatment choice:  In market research, HCPs often say that they choose Venofer because of its safety profile and tolerability • Strong presence in non-HD se

  40. Slide 40: Injectafer: High-dose IV Iron with Broad Indication

    Injectafer®: High-dose IV Iron with Broad Indication • Broader indication – Treatment of IDA in adult patients who have:  Intolerance to oral iron or who have had unsatisfactory response to oral iron or;  Non-dialysis dependent chronic kidney disease • Convenient dosing & administration IV Infusio

  41. Slide 41: Comparison between Injectafer and Venofer

    Comparison between Injectafer® and Venofer ® Injectafer® Venofer ® Molecule Carbohydrate shell Carboxymaltose Sucrose Yes IDA of various of non-CKD etiologies (for adult patients who have Not FDA approved Indications (e.g., cancer, GI disorders, HUB, postpartum) intolerance to oral iron or have had

  42. Slide 42: Injectafer: The Fastest Growing IV Iron in US

    Injectafer: The Fastest Growing IV Iron in US The IV Iron Market grew 15% in $ and 7% in mg volume from MAT August 2014 to MAT August 2015 IV Iron $ sales IV Iron mg sales 700 635.6 2,500 600 552.4 16% 1,983 509.1 6% 2,000 1,853 500 1,737 2% 5% 15% 17% 17% 8% 7% 7% 9% 8% 11% 10% 400 8% 6% 1,500 11%

  43. Slide 43: Hem-Onc Treats most Non-Dialysis IDA patients

    Hem-Onc Treats most Non-Dialysis IDA patients Etiologies Chronic IBD/ of IDA Rheum Dialysis Women’s Heart Celiac/ Oncology RLS Dependent Health ND-CKD HUB patients Post Failure GI patients Other CKD Partum patients patients IDAs Pregnancy Patients’ Visit to Hospitals / Clinics / Physician Office Nep

  44. Slide 44: Growth Strategy for Injectafer

    Growth Strategy for Injectafer Build on Market share leadership in Differentiate Hem-Onc Market Injectafer from expansion into other treatment new therapeutic options Raise areas awareness of IDA among IDA is under-diagnosed physicians & & under-treated patients 43

  45. Slide 45: LPI - A Diversified Specialty Company

    LPI - A Diversified Specialty Company LPI successfully competes in high value specialty branded & generic injectable market segments. Business Domains Strategic Imperatives Build Injectafer into our IRON FRANCHISE flagship product & (> 50% share of non HD segment) market leader GENERIC INJECTABLE Ma

  46. Slide 46: US Generic Injectable Business

    US Generic Injectable Business • Market: $22.8 billion in sales (2.2 billion units) with consistent growth trends • Dynamic market with much price / demand volatility • Drug shortages still remain but are abating 45 Source: IMS NSP AUDIT MAT Sept 2015. Includes Generic and Branded Generic Injectable

  47. Slide 47: LPI's Generic Injectable Business

    LPI’s Generic Injectable Business • Focused on small volume vials and ampules • Over 50 products in active production & lineup is increasing  Building inventory of key products to alleviate market shortages • The business is growing rapidly 46

  48. Slide 48: Growth Strategy for Generic Injectable Business

    Growth Strategy for Generic Injectable Business • Launch 5 new products in FY15 • ≈2 dozen products under active FDA review / pending approval • >2 dozen products in active development High portfolio differentiation Strong Consistent relationships to supply of quickly identify products with market h

  49. Slide 49: Investment to Expand Manufacturing Capacity

    Investment to Expand Manufacturing Capacity Consistent supply Intensive LPI’s growing of products with market needs pipeline high quality Capacity Expansion Shirley: Upgrade existing manufacturing infrastructure New Albany: Consolidate operation & capacity expansion Hilliard: Maximize space use & ca

  50. Slide 50: LPI is Positioned for Accelerated Growth

    LPI is Positioned for Accelerated Growth Double digit revenue and profit growth ($M)$ 714 522 395 * * * LE * Based on the forecast 49

  51. Slide 51: Daiichi Sankyo Co., Ltd. Corporate Communications Department

    Contact address regarding this material Daiichi Sankyo Co., Ltd. Corporate Communications Department TEL: +81-3-6225-1126 Financial forecasts, future projections and R&D information that Daiichi Sankyo discloses may include information that might be classified as “Forward Looking Statement”. These f

Daiichi Sankyo Company — Q2 FY2015 Earnings Presentation on 6ix